Adequan® Champions the Sport of Dressage
Written by Betsy LaBelle - In Dressage Directory - Thursday, February 12, 2015
Adequan® i.m. (polysulfated glycosaminoglycan), the only product approved by the FDA for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses, has been a great help to the sport of Dressage. For the past 25 years, veterinarians have depended on Adequan® for the treatment of degenerative joint disease in horses.
Luitpold Animal Health, manufacturer of Adequan®, has been committed to supporting the sport through its continuing annual sponsorship of the Adequan® Global Dressage Festival circuit in Wellington, Florida, the US Dressage Finals in November 2014 and the Adequan®/USDF Annual Convention held this past December in Massachusetts. The impact of Adequan® and Luitpold Animal Health relates not only to equine joint health, but also to sponsoring prize money for the utmost results from the top riders in their advancement on the Fédération Equestre Internationale (FEI) World Dressage Ranking List.
Proper equine joint function is a precise and harmonious system of tissues that provide strength, stability and protection while allowing a broad range of movement and flexibility. When in a balanced state, healthy joints provide an efficient mechanism to restore aged cells and stimulate repair for minimal loss to the essential joint cartilage. This ongoing wear-and-repair cycle, however, can become overwhelmed and insufficient when joints are overloaded from training, excessive use, athletic endeavors, weak conformation or unbalanced feet.
Polysulfated glycosaminoglycan (PSGAG), marketed as Adequan® i.m., contains a naturally-occurring complex molecule that is the essential building block of the cartilage matrix. Evaluated in a clinical study, this disease-modifying osteoarthritis drug stimulates chondrocytes in production of articular cartilage while relieving painful symptoms and improving joint function.
Adequan® i.m., labeled for intramuscular use, is a potent enzyme inhibitor that addresses degenerative joint disease in the carpal or hock joints while stimulating cartilage repair and reversing joint disease. Extensive studies of Adequan® i.m. have proven that it passes through the synovial membrane and is absorbed into the articular cartilage.
Adequan® is clinically proven to relieve symptoms and treat the underlying causes of non-infectious equine degenerative joint disease. The FDA labeled dosage and administration is 500 mg every four days, for 28 days intramuscularly.
Below is a short summary of the degenerative joint disease (DJD) cycle from detection of joint dysfunction to repair:
• Mild joint pain, inflammation and difficulty with performance are early stages indicating non-infectious osteoarthritis or DJD.
• Adequan® i.m. treatment inhibits destructive enzymes that attack synovial fluid in joints and cartilage a critical component to improve and restore joint movement.
• Within two hours of administration of Adequan® i.m., the active ingredient (PSGAG) reaches peak therapeutic levels in the joint.
• 48 hours after administration of Adequan® i.m., the hyaluronic acid (HA) nearly doubles in the synovial fluid.
• For at least 96 hours after application, Adequan® i.m. is detected at a therapeutic level in articular cartilage and subchondral bone
Luitpold Animal Health maintains the highest standards on quality and safety.
Through its continuing annual sponsorship of the Adequan® Global Dressage Festival circuit in Wellington, Florida and the United States Dressage Federation, Luitpold Animal Health and Adequan®, instrumental in equine joint health, also prepares riders and their horses for the world stage in competition. The horses and riders build their foundations for the year as strong international competitors in Wellington, Florida in order to take on the big European riders throughout the summer and fall to achieve the highest results ever, with a special thanks to Adequan®.
Adequan® i.m.: For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. There are no known contraindications to the use of intramuscular Adequan® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. Each 5 mL contains 500 mg Polysulfated Glycosaminoglycan. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
SEE PRODUCT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION by going to www.adequan.com, or by calling (800) 458-0163. Adequan® is a registered trademark of Luitpold Pharmaceuticals, Inc. ©LUITPOLD PHARMACEUTICALS, INC., Animal Health Division, Shirley, NY 11967. © 2014
To learn more about the equine joint, click here:
There is no generic Adequan®:
Written by Betsy LaBelle for Dressage Headlines - www.dressageheadlines.com